Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison
Smitha Antony(United States Department of Health and Human Services), Yves Pommier(National Cancer Institute), Muthusamy Jayaraman(Forma Therapeutics (United States)), Keli Agama, Glenda Kohlhagen(Purdue University West Lafayette), Farukh A. Durrani, Mark Cushman(University of Indianapolis), Youcef M. Rustum(University of Iowa), Shousong Cao(Southwest Medical University)
Cited by 71
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
|Nature Biotechnology|2008|1.2k